Inactive Instrument

Emisphere Technologies, Inc.

Equities

EMIS

US2913451066

Biotechnology & Medical Research

Emisphere Technologies, Inc. Appoints Alan Gallantar as Interim Chief Financial Officer

June 28, 2016 at 05:01 pm EDT

On June 22, 2016, Emisphere Technologies, Inc. appointed Alan Gallantar as its interim chief financial officer effective as of June 25, 2016. Mr. Gallantar previously from July 2015 until April 2016, served as chief financial officer of OmniSeq, LLC.

Latest news about Emisphere Technologies, Inc.

Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Emisphere Technologies, Inc..	20-12-07	CI
Novo Nordisk A/S : to boost pill-form diabetic drugs with $1.8 billion deal	20-11-06	RE
Novo Nordisk A/S : to Buy Emisphere Technologies and Drug-Delivery Platform for $1.8 Billion	20-11-06	DJ
Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Emisphere Technologies, Inc. for $1.34 billion.	20-11-05	CI
Emisphere Technologies, Inc. Announces Management Changes	19-09-10	CI
Emisphere Technologies, Inc. Amends License Agreement with Novo Nordisk	18-04-26	CI
Emisphere Technologies, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2017	17-05-12	CI
Emisphere Technologies, Inc. Auditor Raises 'Going Concern' Doubt	17-03-29	CI
Emisphere Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-03-29	CI
Emisphere Restructures Debt Agreements	16-12-09	CI
Emisphere Technologies, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-14	CI
Emisphere Technologies, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-08-15	CI
Emisphere Technologies To Sell Eligen B12	16-08-15	CI
Emisphere Technologies, Inc. Appoints Alan Gallantar as Interim Chief Financial Officer	16-06-28	CI
Emisphere Technologies, Inc. Announces Resignation of Michael R. Garone as Vice President & Chief Financial Officer, Effective June 25, 2016	16-06-02	CI
Emisphere Technologies, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	16-05-16	CI
Emisphere Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-30	CI
Emisphere Technologies, Inc. Auditor Raises 'Going Concern' Doubt	16-03-28	CI
Emisphere Technologies, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended of September 30, 2015	15-11-16	CI
Emisphere Technologies, Inc. Enters into Development and License Agreement with Novo Nordisk A/S	15-10-15	CI
Emisphere Highlights Eligen Licensee Novo Nordisk's Entry into Phase 3A Development of Oral Semaglutide	15-08-26	CI
Emisphere Technologies, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-12	CI
Emisphere Technologies, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015	15-05-15	CI
Emisphere Technologies, Inc. Reports Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014	15-03-31	CI
Emisphere Technologies, Inc. Auditor Raises 'Going Concern' Doubt	15-03-30	CI

Chart Emisphere Technologies, Inc.

Duration

Period

More charts

Company Profile

Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research